9. (Currently amended) A compound having the following formula:

wherein at least one of R and R' is a charged ligand and the other one of R and R' is optionally H or a C_1 - C_6 alkyl group.

- 10. (Previously presented) The compound according to claim 9, wherein the charged ligand contains at least one sulfonate group.
 - 11. Cancelled.
- 12. (Currently amended) A method for inhibiting <u>cell surface protein disulfide isomerase</u>
 (PDI) <u>compounds comprising exposing cells expressing PDI</u> to a compound according to claim 9 in an amount sufficient to inhibit PDI activity.
- 13. (Currently amended) The method of claim 12, wherein PDI activity is 35 measured by assaying L-selectin shedding from leucocytes or lymphocytes.
- 14. (Previously presented) A method for treating a mammal for a viral infection propagated by PDI-mediated virion entry into host cells comprising administering to the mammal the compound of claim 9 in an amount sufficient to inhibit viral propagation.
- 15. (Previously presented) The method of claim 14, wherein the viral infection is an HIV infection.

First Amendment/Response S.N. 10/002,698 September, 2004 N12-018DIV1

16-18. Cancelled.

- 19. (Currently amended) A method for determining optimum blood concentrations of a PDI inhibitor compound according to claim 9 for treatment of a mammal for a viral infection comprising: admixing a blood sample with the said compound of claim 9 and assaying for leucocyte L-selectin shedding.
- 20. (Previously presented) The compound of claim 9, wherein said compound is a membrane impermeable inhibitor of protein disuflide isomerase (PDI).
- 21. (Previously presented) The method of claim 19, wherein the viral infection is an HIV infection.